Table A.3.
Demographic and baseline clinical characteristics of second-line therapy.
| Demographic characteristics | Second-line therapy |
||||
|---|---|---|---|---|---|
| With PN |
Without PN |
p value | |||
|
n = 280 |
n = 1532 |
||||
| n/mean | %/SD | n/mean | %/SD | ||
| Age (mean, SD) | 62.8 | 10.35 | 62.3 | 11.09 | 0.418 |
| Age group (n, %) | |||||
| 18–34 | 4 | 1.4% | 6 | 0.4% | 0.054 |
| 35–44 | 5 | 1.8% | 60 | 3.9% | 0.078 |
| 45–54 | 47 | 16.8% | 309 | 20.2% | 0.190 |
| 55–64 | 110 | 39.3% | 617 | 40.3% | 0.756 |
| 65–74 | 74 | 26.4% | 281 | 18.3% | 0.002 |
| 75+ | 40 | 14.3% | 259 | 16.9% | 0.277 |
| Sex (n, %) | |||||
| Male | 178 | 63.6% | 926 | 60.4% | 0.324 |
| Female | 102 | 36.4% | 606 | 39.6% | 0.324 |
| Payer (n, %) | |||||
| Commercial | 164 | 58.6% | 981 | 64.0% | 0.081 |
| Medicare | 116 | 41.4% | 551 | 36.0% | 0.081 |
| Insurance plan type (n, %) | |||||
| Comprehensive | 46 | 16.4% | 260 | 17.0% | 0.824 |
| Exclusive-provider organization | 2 | 0.7% | 16 | 1.0% | 1.000 |
| Health-maintenance organization | 43 | 15.4% | 188 | 12.3% | 0.155 |
| Point of service (POS) | 17 | 6.1% | 96 | 6.3% | 0.901 |
| Preferred-provider organization | 150 | 53.6% | 854 | 55.7% | 0.501 |
| POS with capitation | 2 | 0.7% | 9 | 0.6% | 0.682 |
| Consumer-driven health plan | 12 | 4.3% | 76 | 5.0% | 0.629 |
| High-deductible health plan | 8 | 2.9% | 33 | 2.2% | 0.467 |
| Unknown | 0 | 0.0% | 0 | 0.0% | |
| Geographic region (n, %) | |||||
| Northeast | 51 | 18.2% | 256 | 16.7% | 0.537 |
| North central | 70 | 25.0% | 431 | 28.1% | 0.281 |
| South | 107 | 38.2% | 582 | 38.0% | 0.943 |
| West | 50 | 17.9% | 249 | 16.3% | 0.506 |
| Unknown | 2 | 0.7% | 14 | 0.9% | 1.000 |
| Population density (n, %) | |||||
| Urban | 242 | 86.4% | 1,294 | 84.5% | 0.400 |
| Rural | 36 | 12.9% | 224 | 14.6% | 0.439 |
| Unknown | 2 | 0.7% | 14 | 0.9% | 1.000 |
| Duration of line of therapy (mean, SD) | 171.2 | 199.7 | 201.0 | 249.9 | 0.059 |
| DCI (mean, SD) | 4.7 | 2.95 | 4.3 | 2.78 | 0.03 |
| DCI (n, %) | |||||
| 0 | 1 | 0.4% | 18 | 1.2% | 0.340 |
| 1 | 1 | 0.4% | 8 | 0.5% | 1.000 |
| 2 | 96 | 34.3% | 547 | 35.7% | 0.648 |
| 3+ | 182 | 65.0% | 959 | 62.6% | 0.444 |
| DCI components (n, %) | |||||
| Myocardial infarction | 11 | 3.9% | 43 | 2.8% | 0.310 |
| Congestive heart failure | 16 | 5.7% | 92 | 6.0% | 0.850 |
| Peripheral vascular disease | 7 | 2.5% | 53 | 3.5% | 0.409 |
| Cerebrovascular disease | 19 | 6.8% | 92 | 6.0% | 0.617 |
| Dementia | 0 | 0.0% | 4 | 0.3% | |
| Chronic pulmonary disease | 44 | 15.7% | 225 | 14.7% | 0.657 |
| Rheumatologic disease | 3 | 1.1% | 32 | 2.1% | 0.255 |
| Peptic ulcer disease | 7 | 2.5% | 28 | 1.8% | 0.452 |
| Mild liver disease | 1 | 0.4% | 6 | 0.4% | 1.000 |
| Diabetes (mild to moderate) | 66 | 23.6% | 311 | 20.3% | 0.215 |
| Diabetes with chronic complications | 20 | 7.1% | 70 | 4.6% | 0.068 |
| Hemiplegia or paraplegia | 0 | 0.0% | 9 | 0.6% | |
| Renal disease | 73 | 26.1% | 334 | 21.8% | 0.115 |
| Moderate or severe liver disease | 0 | 0.0% | 2 | 0.1% | |
| Human immunodeficiency virus | 0 | 0.0% | 6 | 0.4% | |
| Any malignancy, including lymphoma and leukemia | 247 | 88.2% | 1,434 | 93.6% | 0.001 |
| Metastatic solid tumor | 50 | 17.9% | 244 | 15.9% | 0.421 |
| Prior primary cancer (n, %) | |||||
| Solid tumor | 59 | 21.1% | 325 | 21.2% | 0.957 |
| Hematologic cancer | 40 | 14.3% | 189 | 12.3% | 0.367 |
| Preperiod events of interest (n, %) | |||||
| Chronic kidney disease | 59 | 21.1% | 250 | 16.3% | 0.052 |
| End-stage renal disease/renal failure | 14 | 5.0% | 76 | 5.0% | 0.978 |
| Skeletal-related events | 138 | 49.3% | 738 | 48.2% | 0.732 |
| Hypercalcemia | 41 | 14.6% | 222 | 14.5% | 0.947 |
| Venous thromboembolism | 13 | 4.6% | 64 | 4.2% | 0.723 |
| Neutropenia | 7 | 2.5% | 50 | 3.3% | 0.501 |
| Pneumonia | 22 | 7.9% | 129 | 8.4% | 0.754 |
| Major bleeding | 5 | 1.8% | 22 | 1.4% | 0.595 |
| GI bleeding | 15 | 5.4% | 77 | 5.0% | 0.817 |
| Anemia | 163 | 58.2% | 825 | 53.9% | 0.178 |
| Anemia or anemia treatment | 163 | 58.2% | 829 | 54.1% | 0.205 |
| Thrombocytopenia | 29 | 10.4% | 100 | 6.5% | 0.022 |
| Amyloidosis | 10 | 3.6% | 34 | 2.2% | 0.177 |
DCI, Deyo–Charlson Comorbidity Index; GI, gastrointestinal; PN, peripheral neuropathy; SD, standard deviation.